Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study
BackgroundObesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-03-01
|
| Series: | Journal of Medical Internet Research |
| Online Access: | https://www.jmir.org/2025/1/e69466 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849391289984876544 |
|---|---|
| author | Hans Johnson David Huang Vivian Liu Mahmoud Al Ammouri Christopher Jacobs Austen El-Osta |
| author_facet | Hans Johnson David Huang Vivian Liu Mahmoud Al Ammouri Christopher Jacobs Austen El-Osta |
| author_sort | Hans Johnson |
| collection | DOAJ |
| description |
BackgroundObesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight loss among users. Digital health platforms offering behavioral support may enhance the effectiveness of these medications.
ObjectiveThis retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor agonists (semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (tirzepatide) in the United Kingdom over 5 months.
MethodsData were collected from the Voy weight loss digital health platform between February 2023 and August 2024. Participants were adults aged 18-75 years with a BMI ≥30 or ≥27.5 kg/m2 with the presence of obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide. Engagement was defined based on attendance at coaching sessions, frequency of app use, and regular weight tracking. Participants were categorized as “engaged” or “nonengaged” accordingly. Weight loss outcomes were assessed over a period of up to 5 months. Statistical analyses included chi-square tests, independent t tests, Kaplan-Meier survival analysis, and calculations of Cohen d for effect sizes.
ResultsA total of 57,975 participants were included in the analysis, with 31,407 (54.2%) classified as engaged and 26,568 (45.8%) as nonengaged. Engaged participants achieved significantly greater weight loss at each time point. At month 3, engaged participants had a mean weight loss of 9% (95% CI 9% to 9.1%) compared with 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001), representing a mean difference of 3.1 percentage points (95% CI 3.1% to 3.1%). A Cohen d effect size of 0.89 indicated a large effect. At month 5, engaged participants had a mean weight loss of 11.53% (95% CI 11.5% to 11.6%) compared with 8% (95% CI 7.9% to 8%) in the nonengaged participants (P<.001). A Cohen d effect size of 0.56 indicated a moderate effect. Participants using tirzepatide achieved more significant weight loss than those using semaglutide at month 5 (13.9%, 95% CI 13.5% to 14.3% vs 9.5%, 95% CI 9.2% to 9.7%; P<.001). The proportion of engaged participants achieving ≥5%, ≥10%, and ≥15% weight loss was significantly higher than the nonengaged group at corresponding time points from months 3 to 5 respectively (P<.001).
ConclusionsEngagement with a digital weight management platform significantly enhances weight loss outcomes among individuals using GLP-1 receptor agonists. The combination of pharmacotherapy and digital behavioral support offers a promising strategy to promote the supported self-care journey of individuals seeking clinically effective obesity management interventions. |
| format | Article |
| id | doaj-art-1ef6b316a9ab40c48fdc7af3d7ded91e |
| institution | Kabale University |
| issn | 1438-8871 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | Journal of Medical Internet Research |
| spelling | doaj-art-1ef6b316a9ab40c48fdc7af3d7ded91e2025-08-20T03:41:07ZengJMIR PublicationsJournal of Medical Internet Research1438-88712025-03-0127e6946610.2196/69466Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation StudyHans Johnsonhttps://orcid.org/0000-0002-2001-4544David Huanghttps://orcid.org/0000-0001-8104-6825Vivian Liuhttps://orcid.org/0009-0005-9013-4022Mahmoud Al Ammourihttps://orcid.org/0009-0007-6184-6818Christopher Jacobshttps://orcid.org/0000-0002-3638-5454Austen El-Ostahttps://orcid.org/0000-0002-8772-4938 BackgroundObesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), have led to significant weight loss among users. Digital health platforms offering behavioral support may enhance the effectiveness of these medications. ObjectiveThis retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor agonists (semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (tirzepatide) in the United Kingdom over 5 months. MethodsData were collected from the Voy weight loss digital health platform between February 2023 and August 2024. Participants were adults aged 18-75 years with a BMI ≥30 or ≥27.5 kg/m2 with the presence of obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide. Engagement was defined based on attendance at coaching sessions, frequency of app use, and regular weight tracking. Participants were categorized as “engaged” or “nonengaged” accordingly. Weight loss outcomes were assessed over a period of up to 5 months. Statistical analyses included chi-square tests, independent t tests, Kaplan-Meier survival analysis, and calculations of Cohen d for effect sizes. ResultsA total of 57,975 participants were included in the analysis, with 31,407 (54.2%) classified as engaged and 26,568 (45.8%) as nonengaged. Engaged participants achieved significantly greater weight loss at each time point. At month 3, engaged participants had a mean weight loss of 9% (95% CI 9% to 9.1%) compared with 5.9% (95% CI 5.9% to 6%) in nonengaged participants (P<.001), representing a mean difference of 3.1 percentage points (95% CI 3.1% to 3.1%). A Cohen d effect size of 0.89 indicated a large effect. At month 5, engaged participants had a mean weight loss of 11.53% (95% CI 11.5% to 11.6%) compared with 8% (95% CI 7.9% to 8%) in the nonengaged participants (P<.001). A Cohen d effect size of 0.56 indicated a moderate effect. Participants using tirzepatide achieved more significant weight loss than those using semaglutide at month 5 (13.9%, 95% CI 13.5% to 14.3% vs 9.5%, 95% CI 9.2% to 9.7%; P<.001). The proportion of engaged participants achieving ≥5%, ≥10%, and ≥15% weight loss was significantly higher than the nonengaged group at corresponding time points from months 3 to 5 respectively (P<.001). ConclusionsEngagement with a digital weight management platform significantly enhances weight loss outcomes among individuals using GLP-1 receptor agonists. The combination of pharmacotherapy and digital behavioral support offers a promising strategy to promote the supported self-care journey of individuals seeking clinically effective obesity management interventions.https://www.jmir.org/2025/1/e69466 |
| spellingShingle | Hans Johnson David Huang Vivian Liu Mahmoud Al Ammouri Christopher Jacobs Austen El-Osta Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study Journal of Medical Internet Research |
| title | Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study |
| title_full | Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study |
| title_fullStr | Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study |
| title_full_unstemmed | Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study |
| title_short | Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study |
| title_sort | impact of digital engagement on weight loss outcomes in obesity management among individuals using glp 1 and dual glp 1 gip receptor agonist therapy retrospective cohort service evaluation study |
| url | https://www.jmir.org/2025/1/e69466 |
| work_keys_str_mv | AT hansjohnson impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy AT davidhuang impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy AT vivianliu impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy AT mahmoudalammouri impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy AT christopherjacobs impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy AT austenelosta impactofdigitalengagementonweightlossoutcomesinobesitymanagementamongindividualsusingglp1anddualglp1gipreceptoragonisttherapyretrospectivecohortserviceevaluationstudy |